Bioenergetics of the calf muscle in Friedreich ataxia patients measured by 31P-MRS before and after treatment with recombinant human erythropoietin.
<h4>Unlabelled</h4>Friedreich ataxia (FRDA) is caused by a GAA repeat expansion in the FXN gene leading to reduced expression of the mitochondrial protein frataxin. Recombinant human erythropoietin (rhuEPO) is suggested to increase frataxin levels, alter mitochondrial function and improv...
Guardado en:
Autores principales: | Wolfgang Nachbauer, Sylvia Boesch, Rainer Schneider, Andreas Eigentler, Julia Wanschitz, Werner Poewe, Michael Schocke |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2344588afa6b4c23af8c6513c0d70044 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Friedreichs ataxia in a diabetic patient
por: Inna Igorevna Klefortova, et al.
Publicado: (2010) -
Current and emerging treatment options in the management of Friedreich ataxia
por: Michelangelo Mancuso, et al.
Publicado: (2010) -
Epigenetic Heterogeneity in Friedreich Ataxia Underlies Variable FXN Reactivation
por: Layne N. Rodden, et al.
Publicado: (2021) -
PGC-1alpha down-regulation affects the antioxidant response in Friedreich's ataxia.
por: Daniele Marmolino, et al.
Publicado: (2010) -
Digital endpoints for self‐administered home‐based functional assessment in pediatric Friedreich’s ataxia
por: Arne Mueller, et al.
Publicado: (2021)